{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Taylor ML"],"funding":["NICHD NIH HHS","NIAID NIH HHS","NIAMS NIH HHS"],"pagination":["1042-1051"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9588491"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["49(9)"],"pubmed_abstract":["<h4>Objective</h4>To compare clinical outcomes in children with hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) who were managed before and after implementation of an evidence-based guideline (EBG).<h4>Methods</h4>A management algorithm for MAS-HLH was developed at our institution based on literature review, expert opinion, and consensus building across multiple pediatric subspecialties. An electronic medical record search retrospectively identified hospitalized patients with MAS-HLH in the pre-EBG (October 15, 2015, to December 4, 2017) and post-EBG (January 1, 2018, to January 21, 2020) time periods. Predetermined outcome metrics were evaluated in the 2 cohorts.<h4>Results</h4>After the EBG launch, 57 children were identified by house staff as potential "],"journal":["The Journal of rheumatology"],"pubmed_title":["An Evidence-Based Guideline Improves Outcomes for Patients With Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome."],"pmcid":["PMC9588491"],"funding_grant_id":["K08 AR073339","K12 HD052896","P30 AR070253","T32 AI007512"],"pubmed_authors":["Meidan E","Son MBF","Benson L","Lee PY","Hazen MM","Halyabar O","Chang MH","Chandler MT","Cohen EM","Hausmann JS","Gorman M","Case S","Lo MS","Platt C","Degar B","Henderson LA","Taylor ML","Lo J","Priebe GP","Nigrovic PA","Janssen E","Roberts JE","Sundel RP","Yeun JC","Hoyt KJ","Day-Lewis M","Alfieri M","Shobiye DM","Han J","Dedeoglu F","Chang JC"],"additional_accession":[]},"is_claimable":false,"name":"An Evidence-Based Guideline Improves Outcomes for Patients With Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome.","description":"<h4>Objective</h4>To compare clinical outcomes in children with hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) who were managed before and after implementation of an evidence-based guideline (EBG).<h4>Methods</h4>A management algorithm for MAS-HLH was developed at our institution based on literature review, expert opinion, and consensus building across multiple pediatric subspecialties. An electronic medical record search retrospectively identified hospitalized patients with MAS-HLH in the pre-EBG (October 15, 2015, to December 4, 2017) and post-EBG (January 1, 2018, to January 21, 2020) time periods. Predetermined outcome metrics were evaluated in the 2 cohorts.<h4>Results</h4>After the EBG launch, 57 children were identified by house staff as potential ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-04T20:04:36.169Z","creation":"2025-04-04T20:04:36.169Z"},"accession":"S-EPMC9588491","cross_references":{"pubmed":["35840156"],"doi":["10.3899/jrheum.211219"]}}